NCT01244633

Ecopipam Treatment of Tourette Syndrome

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Psyadon Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.

Detailed description

Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. Although its causes are unknown, many researchers believe that changes in brain chemicals (called neurotransmitters) are critically involved. One of these neurotransmitters is called dopamine, and it exerts its actions through its receptors (called D1-type or D2-type). It has been suggested that the symptoms of Tourette's Syndrome are due to an overactivity at the D1-type receptor. Ecopipam is a selective antagonist of the D1-type receptors. The present clinical trial is designed to test if ecopipam is able to relieve the symptoms of the disease in adults patients with Tourette's Syndrome. Eligible patients will be treated for eight weeks.

Conditions

• Tourette's Syndrome

Interventions

Type	Name	Description
DRUG	Ecopipam	50 or 100 mg tablets given once per day for eight weeks

Timeline

• Start date: 2010-10-01
• Primary completion: 2012-07-01
• Completion: 2013-07-01
• First posted: 2010-11-19
• Last updated: 2015-09-29
• Results posted: 2015-09-29

Locations

4 sites across 1 country: United States